rosiglitazone has been researched along with Nerve Degeneration in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carta, AR; Lecca, D; Mulas, G; Pisanu, A; Simbula, G; Spiga, S; Wardas, J | 1 |
| Inestrosa, NC; Toledo, EM | 1 |
| Byun, K; Choi, JH; Hwang, IK; Kim, YM; Lee, B; Lee, CH; Park, OK; Won, MH; Yoo, KY | 1 |
| Koh, HC; Lee, EY; Lee, JE; Park, JH; Shin, IC | 1 |
| Deng, YC; Huang, YG; Li, YN; Shao, XG; Sun, H; Yang, J; Yu, X | 1 |
5 other study(ies) available for rosiglitazone and Nerve Degeneration
| Article | Year |
|---|---|
Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease.
Topics: Animals; Cell Count; Cell Polarity; Cytokines; Disease Models, Animal; Gene Expression Regulation; Mice; Microglia; MPTP Poisoning; Nerve Degeneration; Neuroprotective Agents; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Tyrosine 3-Monooxygenase | 2014 |
Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Astrocytes; Brain; Disease Models, Animal; Inflammation; Lithium Compounds; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Nerve Degeneration; Nerve Tissue Proteins; Presenilin-1; Rosiglitazone; Signal Transduction; Thiazolidinediones; Wnt Proteins | 2010 |
The role of peroxisome proliferator-activated receptor γ, and effects of its agonist, rosiglitazone, on transient cerebral ischemic damage.
Topics: Animals; Astrocytes; CA1 Region, Hippocampal; Cell Death; Disease Models, Animal; Gerbillinae; Interleukin-13; Interleukin-4; Ischemic Attack, Transient; Male; Microglia; Nerve Degeneration; Neuroprotective Agents; PPAR gamma; Reperfusion; Rosiglitazone; Thiazolidinediones | 2011 |
Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Topics: Animals; Basal Ganglia; Calcium-Binding Proteins; Cyclooxygenase 2; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Glial Fibrillary Acidic Protein; Injections, Intraperitoneal; Male; Microfilament Proteins; Nerve Degeneration; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Substantia Nigra; Thiazolidinediones; Time Factors; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase | 2012 |
Activation of cerebral peroxisome proliferator-activated receptors gamma exerts neuroprotection by inhibiting oxidative stress following pilocarpine-induced status epilepticus.
Topics: Animals; Benzamides; Cell Death; Convulsants; Disease Models, Animal; Glutathione; Heme Oxygenase (Decyclizing); Hippocampus; Lipid Peroxidation; Lithium; Male; Muscarinic Agonists; Nerve Degeneration; Neuroprotective Agents; Oxidative Stress; Pilocarpine; PPAR gamma; Pyridines; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Rosiglitazone; Status Epilepticus; Superoxide Dismutase; Superoxide Dismutase-1; Thiazolidinediones | 2008 |